Clinical Trial Update: Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial evaluated arsenic trioxide in pancreatic cancer patients who were resistant to gemcitabine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Arsenic Trioxide (Trisenox) (arsenic trioxide)

Snippet

Sponsor: University of Chicago | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED